Class Action Signal

Class Action Signal

Class ActionsNews
Class ActionsNewsAboutContact
Public case informationLast updated

Replimune Securities Fraud Class Action

Replimune Group · Replimune securities and RP1 therapy development program · New Filing

About this case

A securities class action has been filed against Replimune and certain officers and directors, alleging securities fraud or other unlawful business practices related to disclosures about the FDA's rejection of the company's biologics license application for RP1 in combination with nivolumab. The matter is at the filing stage, with investors able to seek appointment as lead plaintiff by October 5, 2026.

Case overview

Defendant company
Replimune Group
Product or service
Replimune securities and RP1 therapy development program
Case name
Toor v. Replimune Group, Inc. et al.
Court case number
1:26-cv-13612
Case status
New Filing
Lawsuit type
Securities
Reported harm
Misrepresentation

Important dates

Lead Plaintiff Application
Lead Plaintiff Application

Participation information

Lead Plaintiff Application

Investors who purchased or otherwise acquired Replimune securities during the class period may ask the court to appoint them as lead plaintiff.

Contact Pomerantz LLP at newaction@pomlaw.com or 646-581-9980, or 888-4-POMLAW, extension 7980. Email inquiries are encouraged to include a mailing address, telephone number, and number of shares purchased.

Type
Lead Plaintiff
Status
Open
Reported proof requirement
Unclear
Apply as lead plaintiff

Lead Plaintiff Application

Persons or entities that purchased or otherwise acquired Replimune Group securities between October 20, 2025 and April 10, 2026 may seek appointment as lead plaintiff.

Move the court to serve as lead plaintiff no later than 60 days from the August 7, 2026 notice date.

Type
Lead Plaintiff
Status
Open

Settlement Claim

This is a newly filed securities class action, not a verified settlement. The identified action concerns people or entities who purchased or otherwise acquired Replimune securities from October 20, 2025 through April 10, 2026, inclusive.

No official settlement claim-filing process was verified. The available notice concerns seeking appointment as lead plaintiff, with motions due October 5, 2026; it is not a settlement claim form.

Type
Settlement Claim
Reported proof requirement
Unclear

Replimune investor legal-rights inquiry

The notice concerns people who purchased Replimune shares between October 20, 2025 and April 10, 2026 and experienced a significant investment loss.

Contact Holzer Law through its website for information about potential legal rights.

Type
Law Firm Signup
Announcement Business Wire source Source article Case information Press release Source version

Sources